Pesquisa | BVS IEC

1.

Something old, something new: The marriage of PD-1 and IL-2.

Horton, Brendan L; Spranger, Stefani.

Immunity ; 56(1): 8-10, 2023 01 10.

Artigo em Inglês | MEDLINE | ID: mdl-36630920

2.

Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer.

Zagorulya, Maria; Yim, Leon; Morgan, Duncan M; Edwards, Austin; Torres-Mejia, Elen; Momin, Noor; McCreery, Chloe V; Zamora, Izabella L; Horton, Brendan L; Fox, James G; Wittrup, K Dane; Love, J Christopher; Spranger, Stefani.

Immunity ; 56(2): 386-405.e10, 2023 02 14.

Artigo em Inglês | MEDLINE | ID: mdl-36736322

3.

CD36 - the Achilles' heel of T_reg cells.

Horton, Brendan L; Spranger, Stefani.

Nat Immunol ; 21(3): 251-253, 2020 03.

Artigo em Inglês | MEDLINE | ID: mdl-32066948

4.

A Tumor Cell-Intrinsic Yin-Yang Determining Immune Evasion.

Horton, Brendan; Spranger, Stefani.

Immunity ; 49(1): 11-13, 2018 07 17.

Artigo em Inglês | MEDLINE | ID: mdl-30021140

5.

Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.

Gajewski, Thomas F; Corrales, Leticia; Williams, Jason; Horton, Brendan; Sivan, Ayelet; Spranger, Stefani.

Adv Exp Med Biol ; 1036: 19-31, 2017.

Artigo em Inglês | MEDLINE | ID: mdl-29275462

6.

Batf3⁺ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy.

Ziblat, Andrea; Horton, Brendan L; Higgs, Emily F; Hatogai, Ken; Martinez, Anna; Shapiro, Jason W; Kim, Danny E C; Zha, YuanYuan; Sweis, Randy F; Gajewski, Thomas F.

Cell Rep ; 43(5): 114141, 2024 May 28.

Artigo em Inglês | MEDLINE | ID: mdl-38656869

7.

A prime editor mouse to model a broad spectrum of somatic mutations in vivo.

Ely, Zackery A; Mathey-Andrews, Nicolas; Naranjo, Santiago; Gould, Samuel I; Mercer, Kim L; Newby, Gregory A; Cabana, Christina M; Rideout, William M; Jaramillo, Grissel Cervantes; Khirallah, Jennifer M; Holland, Katie; Randolph, Peyton B; Freed-Pastor, William A; Davis, Jessie R; Kulstad, Zachary; Westcott, Peter M K; Lin, Lin; Anzalone, Andrew V; Horton, Brendan L; Pattada, Nimisha B; Shanahan, Sean-Luc; Ye, Zhongfeng; Spranger, Stefani; Xu, Qiaobing; Sánchez-Rivera, Francisco J; Liu, David R; Jacks, Tyler.

Nat Biotechnol ; 42(3): 424-436, 2024 Mar.

Artigo em Inglês | MEDLINE | ID: mdl-37169967

8.

Back from the dead: TIL apoptosis in cancer immune evasion.

Horton, Brendan L; Gajewski, Thomas F.

Br J Cancer ; 118(3): 309-311, 2018 02 06.

Artigo em Inglês | MEDLINE | ID: mdl-29360810

9.

Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2.

Horton, Brendan L; D'Souza, Alicia D; Zagorulya, Maria; McCreery, Chloe V; Abhiraman, Gita C; Picton, Lora; Sheen, Allison; Agarwal, Yash; Momin, Noor; Wittrup, K Dane; White, Forest M; Garcia, K Christopher; Spranger, Stefani.

JCI Insight ; 8(19)2023 10 09.

Artigo em Inglês | MEDLINE | ID: mdl-37669107

10.

Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies.

Anderson, Kristin G; Braun, David A; Buqué, Aitziber; Gitto, Sarah B; Guerriero, Jennifer L; Horton, Brendan; Keenan, Bridget P; Kim, Teresa S; Overacre-Delgoffe, Abigail; Ruella, Marco; Triplett, Todd A; Veeranki, Omkara; Verma, Vivek; Zhang, Fan.

J Immunother Cancer ; 11(6)2023 06.

Artigo em Inglês | MEDLINE | ID: mdl-37399356

11.

Lack of CD8⁺ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer.

Horton, Brendan L; Morgan, Duncan M; Momin, Noor; Zagorulya, Maria; Torres-Mejia, Elen; Bhandarkar, Vidit; Wittrup, K Dane; Love, J Christopher; Spranger, Stefani.

Sci Immunol ; 6(64): eabi8800, 2021 Oct 29.

Artigo em Inglês | MEDLINE | ID: mdl-34714687

12.

Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras.

Cohen, Malkiel A; Zhang, Shupei; Sengupta, Satyaki; Ma, Haiting; Bell, George W; Horton, Brendan; Sharma, Bandana; George, Rani E; Spranger, Stefani; Jaenisch, Rudolf.

Cell Stem Cell ; 26(4): 579-592.e6, 2020 04 02.

Artigo em Inglês | MEDLINE | ID: mdl-32142683

13.

Tissue Site and the Cancer Immunity Cycle.

Horton, Brendan L; Fessenden, Tim B; Spranger, Stefani.

Trends Cancer ; 5(10): 593-603, 2019 10.

Artigo em Inglês | MEDLINE | ID: mdl-31706507

14.

Intratumoral CD8⁺ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.

Horton, Brendan L; Williams, Jason B; Cabanov, Alexandra; Spranger, Stefani; Gajewski, Thomas F.

Cancer Immunol Res ; 6(1): 14-24, 2018 01.

Artigo em Inglês | MEDLINE | ID: mdl-29097422

15.

The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions.

Horton, Brendan L; Spranger, Stefani.

Emerg Top Life Sci ; 1(5): 447-456, 2017 Dec 12.

Artigo em Inglês | MEDLINE | ID: mdl-33525802

16.

Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

Spranger, Stefani; Dai, Daisy; Horton, Brendan; Gajewski, Thomas F.

Cancer Cell ; 31(5): 711-723.e4, 2017 05 08.

Artigo em Inglês | MEDLINE | ID: mdl-28486109

17.

The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.

Williams, Jason B; Horton, Brendan L; Zheng, Yan; Duan, Yukan; Powell, Jonathan D; Gajewski, Thomas F.

J Exp Med ; 214(2): 381-400, 2017 02.

Artigo em Inglês | MEDLINE | ID: mdl-28115575

18.

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.

Spranger, Stefani; Koblish, Holly K; Horton, Brendan; Scherle, Peggy A; Newton, Robert; Gajewski, Thomas F.

J Immunother Cancer ; 2: 3, 2014.

Artigo em Inglês | MEDLINE | ID: mdl-24829760

19.

Applications matter.

Horton, Brendan.

Nature ; 416(6877): 4-5, 2002 Mar 14.

Artigo em Inglês | MEDLINE | ID: mdl-11894054

BVS IEC

Instituto Evandro Chagas

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar:

Something old, something new: The marriage of PD-1 and IL-2.

Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer.

CD36 - the Achilles' heel of T_reg cells.

A Tumor Cell-Intrinsic Yin-Yang Determining Immune Evasion.

Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.

Batf3⁺ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy.

A prime editor mouse to model a broad spectrum of somatic mutations in vivo.

Back from the dead: TIL apoptosis in cancer immune evasion.

Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2.

Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies.

Lack of CD8⁺ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer.

Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras.

Tissue Site and the Cancer Immunity Cycle.

Intratumoral CD8⁺ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.

The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions.

Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.

Applications matter.